Paying for New Drugs for New Bugs: Regulation is Only One Side of the Coin
This article was originally published in RPM Report
Executive Summary
FDA and Congress are making great strides in improving the regulatory pathway and intellectual property protection for anti-infectives. But without changes in the reimbursement process, the package of incentives may not be enough to spur innovation in the class.